- Approximately 160 people with Amyotrophic Latera Sclerosis (ALS) are now enrolled in the verdiperstat treatment arm of the pivotal HEALEY ALS Platform Trial
- Verdiperstat is an investigational, first-in-class, brain-penetrant, oral small molecule designed to inhibit the myeloperoxidase (MPO) enzyme, a driver of neuroinflammation in ALS and other neurodegenerative diseases
- Amyotrophic Lateral Sclerosis is a progressive, life-threatening, and rare neurodegenerative disease that affects approximately 30,000 people in the United States
PR Newswire
NEW HAVEN, Conn., Nov. 15, 2021